ERBB2 and breast cancer: Although HER2+ BC responds quite well to trastuzumab (HerceptinTM) therapy plus chemotherapy in the early stages of the disease, acquired resistance, however, to trastuzumab after 1–2 years of treatment is a frequent event following metastasis (185).